Dataset Information


Comparison of Lipid-Lowering Effects of Anagliptin and Miglitol in Patients With Type 2 Diabetes: A Randomized Trial.

ABSTRACT: Background:Recently, we reported that the level of lathosterol, a cholesterol synthesis marker, was suppressed after 1 month of treatment with anagliptin, a dipeptidyl peptidase-4 inhibitor. In this study, we administered either anagliptin or miglitol, an alpha-glucosidase inhibitor, for 3 months in patients with type 2 diabetes and compared the lipid-lowering effects of anagliptin with those of miglitol. Methods:This study was a 12-week, open-label, prospective, randomized, parallel-group comparison trial. Fifty-two patients with type 2 diabetes who aged 20 - 70 years with a low-density lipoprotein cholesterol (LDL-C) level of over 120 mg/dL, and with no history of treatment with antihyperlipidemic drugs were enrolled. Patients were randomly assigned to either the anagliptin group or miglitol group. The 100 mg of anagliptin was administered twice a day for the anagliptin group and 50 mg of miglitol was administered thrice a day for miglitol group. The changes in lipids, cholesterol synthesis, and absorption markers were evaluated after 12 weeks. Results:Fifty-two participants were initially enrolled in the trial, and 47 of them completed the protocol. There was no significant difference in LDL-C, cholesterol synthesis, and the absorption markers between anagliptin and miglitol groups. Conclusions:Anagliptin and miglitol are similarly effective on lipid and glycemic control.

PROVIDER: S-EPMC7011936 | BioStudies |

REPOSITORIES: biostudies

Similar Datasets

| S-EPMC4300407 | BioStudies
| S-EPMC6561974 | BioStudies
| S-EPMC5843683 | BioStudies
| S-EPMC6858725 | BioStudies
| S-EPMC7296623 | BioStudies
| S-EPMC7019317 | BioStudies
| S-EPMC8737073 | BioStudies
| S-EPMC5334308 | BioStudies
| S-EPMC6986701 | BioStudies
| S-EPMC6215941 | BioStudies